{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06439914",
            "orgStudyIdInfo": {
                "id": "2023-092"
            },
            "organization": {
                "fullName": "Barbara Ann Karmanos Cancer Institute",
                "class": "OTHER"
            },
            "briefTitle": "First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy",
            "officialTitle": "IFN-y PET Imaging: Bench to Bedside",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "first-in-human-study-of-interferon-y-pet-imaging-to-assess-response-to-immunotherapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-28",
            "studyFirstSubmitQcDate": "2024-05-28",
            "studyFirstPostDateStruct": {
                "date": "2024-06-03",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-28",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Nerissa T. Viola",
                "investigatorTitle": "Principle Investigator",
                "investigatorAffiliation": "Barbara Ann Karmanos Cancer Institute"
            },
            "leadSponsor": {
                "name": "Nerissa T. Viola",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical trial is to investigate the use of \\[89Zr\\]Zr-DFO-emapalumab as an IFN-\u03b3 PET imaging agent to detect lesions and response to therapy among treatment-na\u00efve non-small cell lung cancer (NSCLC) patients. PET scans following the imaging agent will be completed prior to and about 30 days after starting immunotherapy.",
            "detailedDescription": "Participants will be enrolled into the clinical trial once confirmed eligible. Screening activities include, standard of care blood work, medical history and a physical exam.\n\n-Within 14 days of starting immunotherapy, participants will complete PET scans 1-2 hours post-tracer administration, again on the day following tracer administration, and 3-5 days after the tracer administration. This sequence may be repeated 25-45 days after the start of treatment with immunotherapy for a total of two tracer injections and up to six PET scans."
        },
        "conditionsModule": {
            "conditions": [
                "Non Small Cell Lung Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 6,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "[89Zr]Zr-DFO-emapalumab",
                    "type": "EXPERIMENTAL",
                    "description": "Radiotracer \\[89Zr\\]Zr-DFO-emapalumab injection",
                    "interventionNames": [
                        "Drug: [89Zr]Zr-DFO-emapalumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "[89Zr]Zr-DFO-emapalumab",
                    "description": "Radiotracer \\[89Zr\\]Zr-DFO-emapalumab administration followed by 3 PET Scans (day 0, day 1 and day 3-5) within 14 days of starting immunotherapy and repeated once 25-45 days after immunotherapy started",
                    "armGroupLabels": [
                        "[89Zr]Zr-DFO-emapalumab"
                    ],
                    "otherNames": [
                        "Zirconium Zr 89-DFO-emapalumab"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "peak Standard Uptake Value (SUVpeak)",
                    "description": "Descriptively summarize at baseline and post-immunotherapy treatments.",
                    "timeFrame": "Up to Day 45"
                },
                {
                    "measure": "mean Standard Uptake Value (SUVmean)",
                    "description": "Descriptively summarize at baseline and post-immunotherapy treatments.",
                    "timeFrame": "Up to Day 45"
                },
                {
                    "measure": "maximum Standard Uptake Value (SUVmax)",
                    "description": "Descriptively summarize at baseline and post-immunotherapy treatments.",
                    "timeFrame": "Up to Day 45"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "change of SUVpeak",
                    "description": "Descriptively summarize the percent change from baseline to post-immunotherapy treatments.",
                    "timeFrame": "Up to Day 45"
                },
                {
                    "measure": "change of SUVmean",
                    "description": "Descriptively summarize the percent change from baseline to post-immunotherapy treatments.",
                    "timeFrame": "Up to Day 45"
                },
                {
                    "measure": "change of SUVmax",
                    "description": "Descriptively summarize the percent change from baseline to post-immunotherapy treatments.",
                    "timeFrame": "Up to Day 45"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "change of SUVpeak by PET response",
                    "description": "Descriptively summarize the percent change from baseline to post-immunotherapy by PET response",
                    "timeFrame": "Up to Day 45"
                },
                {
                    "measure": "change of SUVmean by PET response",
                    "description": "Descriptively summarize the percent change from baseline to post-immunotherapy by PET response",
                    "timeFrame": "Up to Day 45"
                },
                {
                    "measure": "change of SUVmax by PET response",
                    "description": "Descriptively summarize the percent change from baseline to post-immunotherapy by PET response",
                    "timeFrame": "Up to Day 45"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion\n\n* Prior histologic or cytologic diagnosis of non-small cell lung cancer.\n* FDG PET done within 2 months of the baseline imaging, as part of standard-of-care.\n* measurable disease by RECIST 1.1 with at least one lesion of at least 2 cm in a region of the body that can be imaged by PET (e.g.,outside of the liver)\n* must be able to lie still for the tests. Their girth and weight must be suitable to enter the gantry, which varies per tomograph.\n* must be \\>18 years old.\n* Patients must sign an informed consent indicating that they are aware of the investigational nature of this study, in keeping with the policies of the cancer center.\n* Physical exam, CBC and Multiphasic (including electrolytes, BUN, creatinine, total bilirubin, AST, and ALT) must be done within 28 days prior to PET imaging\n\nExclusion\n\n* No prior immunotherapy for current stage of NSCLC (Non Small Cell Lung Cancer). Immunotherapy in neoadjuvant or adjuvant setting and have recurrence at least 12 months following completion of immunotherapy are eligible after discussion with the principle investigator.\n* Pregnant or breast feeding individuals.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Nerissa T Viola, PhD",
                    "role": "CONTACT",
                    "phone": "3135768309",
                    "email": "violan@karmanos.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Nerissa T Viola, PhD",
                    "affiliation": "Barbara Ann Karmanos Cancer Institute",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Karmanos Cancer Institute",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48201",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Nerissa T Viola, PhD",
                            "role": "CONTACT",
                            "phone": "313-576-8309",
                            "email": "violan@karmanos.org"
                        },
                        {
                            "name": "Nerissa T Viola, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Anthony F Shields, MD, PhD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Hirva Mamdani, M.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Dipesh Uprety, M.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Ammar Sukari, M.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Tarik Hadid, MD, MPH, MS",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Otto Muzik, PhD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Huailei Jiang, PhD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                },
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Non-small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10407",
                    "name": "Interferons",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}